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Abstract
Purpose: Noninvasive beta cell mass (BCM) quantification is a crucial tool to understand
diabetes development and progression. [111In]exendin is a promising agent for in vivo beta cell
imaging, but tracer testing has been hampered by the lack of well-defined rodent models.
Procedures: Biodistribution and pancreatic uptake of [111In]exendin were compared in rats and
mice. In selected models, the amount of [111In]exendin accumulation in the pancreas and other
organs was determined using a model of alloxan-induced beta cell loss. GLP-1R expression
levels were analyzed by RT-PCR and immunohistochemistry.
Results: Namely Brown Norway rats showed beta-cell-specific tracer accumulation and
favorable pancreas-to-background ratios for noninvasive BCM determination. Mice displayed
receptor-mediated [111In]exendin uptake in endocrine and exocrine pancreas, in spite of very
low GLP-1R expression in exocrine tissue.
Conclusions: Rats display better characteristics for in vivo BCM determination than mice and are
suggested as a more adequate model for humans.
Key words: Diabetes, Beta cell mass, Receptor targeting, GLP-1R, Exendin
Introduction
Diabetes mellitus is characterized by defective glucose
homeostasis and consequent chronic hyperglycemia.
Maintenance of glycemic control by daily insulin
injections or anti-diabetogenic drugs is difficult, and
patients affected by both type 1 and type 2 diabetes are
at risk for severe complications, such as cardiovascular
disease, blindness, and kidney failure, increasing their
risk for premature death. Changes in beta cell mass
(BCM) occur in both forms of diabetes [1–3], but the
mechanisms and evolution underlying these BCM
changes are poorly understood [4, 5].
Beta cell function is usually monitored by measure-
ments of insulin secretion, such as insulin and C-
peptide, analyzed in parallel to glucose levels.
However, it was shown that beta cell function and
BCM do not diminish equally during disease progres-
sion [5, 6], indicating that beta cell function is not an
adequate measure for BCM. A reliable and reproducible
method to monitor BCM dynamics over time, such as
longitudinal quantitative imaging, could unravel the
importance of BCM during the course of diabetes.
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During the past decade, major efforts have been made to
image BCM in vivo in animal models using a variety of
imaging methodologies [7], such as near infrared optical
projection tomography (OPT) [8], bioluminescence [9], or
magnetic resonance imaging (MRI) [10–12]. While MRI
offers the highest resolution (still not allowing resolution of
single islets in vivo), nuclear medicine imaging modalities,
such as single photon emission computed tomography
(SPECT) and positron emission tomography (PET), have
the potential to reach sufficient sensitivity to detect small
numbers of beta cells when targeted with a radiolabeled
beta-cell-specific tracer. Importantly, the first clinical trial
results show that SPECT and PET are the most likely
approaches to reach human translation at this point in time
[13–15].
A variety of antibodies, such as IC2 [16]; small molecules,
such as 2-deoxy-2-[18F]fluoro-D-glucose [17]; neurotransmitter
precursors, such as [11C]5-hydroxytryptophan ([11C]5-HTP)
[18]; organic compounds, such as dihydrotetrabenazine
(DTBZ) targeting the vesicular monoamine transporter 2
(VMAT2) [19]; and peptides, such as exendin targeting the
glucagon-like peptide 1 (GLP-1) receptor [13] have been
evaluated as tracers for BCM determination. Very recent
findings indicate that [11C]5-HTP can successfully discriminate
between rats with severe or moderate beta cell loss [15, 18],
while radiolabeled exendin, a stable GLP-1R agonist specifically
targeting the pancreatic beta cells [20], was shown to success-
fully detect small changes in BCM in a preclinical model for
beta cell loss [14]. In order to further validate the use of GLP-1R
radionuclide imaging to evaluate the dynamics of BCM changes
in diabetes, further studies in animal models are required.
A variety of preclinical models have been used to
investigate BCM dynamics, but the results obtained
showed differences in biodistribution and in tracer uptake
in relation to BCM [14, 21–24]. We hypothesize that the
observed differences in these studies can be related to
the use of animal models. Therefore, in the present
study, we aimed to evaluate the differences between
various animal models to select the most suitable model
for preclinical, noninvasive BCM determination using
[111In]exendin. Ideally, this optimal model should allow
accurate, quantitative BCM determination and its features
should reflect the human situation. We compared the
biodistribution and pancreatic uptake of [111In]exendin in
various rat and mouse strains and compared their specific
GLP-1R expression pattern. Finally, we determined the
specificity of [111In]exendin accumulation in beta cells
using an alloxan-induced model for beta cell loss.
Materials and Methods
Radiolabeling
[Lys40(DTPA)]exendin-3 (Peptides Specialty Laboratories,
Heidelberg, Germany) was radiolabeled as previously described
[14]. Briefly, 150 MBq [111In]InCl3 was added to 1 μg
[Lys40(DTPA)]exendin-3 dissolved in 0.1 M 2-(N-morpholino)-
ethanesulfonic acid (MES), pH 5.5 (Sigma-Aldrich, St. Louis,
MO, USA) and incubated for 20 min at room temperature
(RT). After incubation, EDTA (Sigma-Aldrich) and Tween 80
(Sigma-Aldrich) were added to a final concentration of 5 mM
and 0.1 %, respectively. The radiochemical purity of
[111In]exendin-3 was determined by instant thin-layer chroma-
tography (ITLC) (ITLC-SG, Agilent Technologies, Lake Forest,
CA, USA), using 0.1 M EDTA in 0.1 M NH4Ac (Sigma-
Aldrich), pH 5.5 as a mobile agent.
Animals
All animal experiments were approved by the Animal Welfare
Committee of the Radboud University, Nijmegen and carried
out in accordance with the local and national guidelines. Six-
to 8-week-old male animals were used for all experiments. For
the experiments in mice, BALB/c, DBA, CBA, and C57Bl/6J
mice were purchased from Janvier Labs (Le Genest Saint Isle,
France) and the NMRI mice from Harlan (Horst, The
Netherlands). For the experiments in rats, Brown Norway,
F344, WAG/Rij, and Sprague Dawley rats were purchased from
Harlan.
Alloxan Treatment
To determine the specificity of [111In]exendin accumulation in
the beta cells, animals were injected with various doses (25–
75 mg/kg) of alloxan monohydrate (Sigma Chemicals, St.
Louis, MO, USA) to deplete the beta cells. Alloxan was
dissolved in ice-cold 10 mM HCl with a concentration of
0.1 mg/μl and diluted with ice-cold phosphate buffered saline
(PBS). During storage and dilution, alloxan was protected from
light and kept on ice. Animals were injected intravenously with
200 μl alloxan solution within 5 min after dilution. Control
animals were injected with vehicle (10 mM HCl diluted with
PBS). Blood glucose concentrations were monitored for 1 week
after alloxan injection using a blood glucose meter (Accu-Chek
Sensor, Roche Diagnostics, Almere, The Netherlands).
Biodistribution Studies
Biodistribution studies were performed to compare the [111In]exendin
uptake in different mouse and rat strains. Based on the
pancreatic uptake, endocrine-to-exocrine ratio, pancreas-to-
stomach ratio, and pancreas-to-duodenum ratio, one strain was
chosen to determine the specificity of [111In]exendin accumu-
lation in the beta cells, as described above. To determine the
effect of alloxan over time, biodistribution studies were
performed on day 1, 3, 5, and 7 after alloxan injection. All
animals used for biodistribution studies were injected intrave-
nously with 15 MBq [111In]exendin-3 (peptide dose 20 pmol/
rat, mouse). Non-GLP-1R-mediated exendin uptake was deter-
mined in a separate group of animals that were coinjected with
an excess of unlabeled exendin (25 μg/animal). Four hours
after injection of the radiolabeled exendin, animals were
euthanized and the pancreas and other relevant tissues (blood,
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muscle, heart, lung, spleen, kidney, liver, stomach, and
duodenum) were dissected, weighed, and counted in a well-
type gamma counter (Wallac 1480 Wizard, Perkin Elmer,
Boston, MA, USA). The percentage injected dose per gram
tissue (%ID/g) was determined for each tissue.
Digital Autoradiography
Ex vivo autoradiography was performed to visualize the uptake in
the islets and the exocrine pancreas. After dissection, pancreata
were fixed in 4 % formalin (w/v), dehydrated, and embedded in
paraffin. Sections of the pancreas (4 μm) were prepared and
exposed to a phosphorimaging plate (Fuji Film BAS-SR 2025,
Raytest, Straubenhardt, Germany) for 7 days. Images were acquired
with a radioluminography laser images (Fuji Film BAS 1800 II
system (Raytest) and analyzed using Aida Image Analyzer software
(Raytest).
Endocrine-to-Exocrine Ratio Determination
To quantitatively compare tracer uptake in the islets and the
exocrine pancreas, endocrine-exocrine uptake ratios were
determined in the autoradiographs of pancreatic sections. The
digital images were analyzed using ImageJ, a public domain
software (http://imagej.nih.gov/ij/). Three pancreatic sections
were analyzed per mouse and rat strain. Per pancreatic section,
three regions of interest (ROI) were drawn in both the exocrine
and endocrine pancreas and the mean density values
(photostimulated luminescence) were determined. These values
were used to calculate the endocrine-exocrine uptake ratio.
Immunohistochemistry
Pancreatic sections (4 μm) of C57Bl/6 mice, Brown Norway
rats, and humans were stained for the presence of GLP-1R.
Antigen retrieval was performed in 10 mM sodium citrate, pH
6.0 for 10 min at 96 °C. Subsequently, sections were incubated
for 10 min with 3 % H2O2 in PBS at RT in the dark, to block
endogenous peroxidase activity. Nonspecific binding was
blocked by incubation for 30 min with 5 % normal swine
serum. The primary anti-GLP-1R antibody (ab39072, Abcam,
Cambridge, UK) was diluted in PBS containing 1 % BSA
(1:500). Primary antibody incubation for 90 min was followed
by incubation with swine-anti-rabbit peroxidase (1:50) (p0271,
DAKO, Copenhagen, Denmark) for 30 min at RT in the dark.
Finally, 3,3′diaminobenzidine (DAB) was used to develop the
pancreatic sections.
Pancreatic Islet Isolation, mRNA Extraction, and
Real-Time PCR
mRNA extraction and real-time PCR was performed as
described previously [25]. Briefly, poly(A)+mRNA was isolated
from pancreatic islets (rat islets were isolated by collagenase
digestion and handpicking and mouse islets using the
Histopaque method [26]) or exocrine tissue (the tissue remain-
ing after islet isolation) from C57Bl/6 mice and Wistar rats
using the Dynabeads mRNA DIRECT™ kit (Invitrogen,
Merelbeke, Belgium) and reversely transcribed. Exocrine
mRNA samples used in the study were evaluated with
Biodrop (Cambridge, UK) and showed a 260/280 ratio 91.9,
suggesting that the mRNA was well preserved. Real-time PCR
amplification of Glp-1r was performed using IQ SyBR Green
Supermix on iCycler MyiQ Single Color (BIO-RAD, Hercules,
CA, USA) and compared to a standard curve. amy2 was
calculated with the deltaCT method [27]. In all assays, the
geometrical means of the housekeeping genes β-actin and
gapdh was used as a reference. The pancreatic islet and
exocrine tissue preparations were selected based on the
expression levels of, respectively, the endocrine marker pdx1
and the exocrine marker amy2. The primers used are listed in
Table 1. Standard curves of the reference genes (β-actin and
gapdh) and Glp1r mRNA expression assays of both rat and
mouse are provided in ESM Fig. 1.
Results
[111In]Exendin Uptake in Various Mouse Strains
Figure 1 shows the biodistribution (two mice per strain) of
[111In]exendin in five mouse strains. As reported previ-
ously [28], tracer uptake was observed not only in the
pancreas but also in various other organs, such as the lung,
stomach, duodenum, and the kidneys. Based on these
results, BALB/c mice showed favorable features for in vivo
beta cell targeting, namely high pancreatic uptake
(36.8 %ID/g) and relatively low uptake in lung
(26.4 %ID/g), stomach (7.37 %ID/g), and duodenum
(9.42 %ID/g). Therefore, BALB/c mice were selected to
determine the specificity of tracer accumulation in the beta
cells. C57Bl/6 mice, a strain often used in diabetes
research, was also evaluated.
Beta Cell Specificity of [111In]Exendin Uptake in
BALB/c and C57Bl/6 Mice
In BALB/c mice, the pancreatic uptake did not decline
after injection of 25, 32.5, 50, and 62.5 mg/kg alloxan
(Fig. 2a). Mice treated with even higher doses of alloxan
(75, 100, 150, and 200 mg/kg) showed increased total
pancreatic tracer uptake. In animals treated with high
alloxan doses, elevated tracer levels in the blood were
observed and thus, higher uptake in all other tissues,
including the exocrine pancreas (Fig. 2a, b). This is most
probably the result of dehydration secondary to severe
hyperglycemia, leading to slower blood clearance. In
addition, direct toxic effects of alloxan cannot be
excluded at high doses. Coinjection of an excess
unlabeled exendin decreased the pancreatic uptake from
7.9 ± 0.6 %ID/g to 0.23 ± 0.04 %ID/g (Fig. 2a) which
was also reflected by the autoradiographic images
(Fig. 2c). Due to the high uptake in exocrine tissue,
the endocrine-exocrine ratio in these mice was only 4.11 ±
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0.93 (Table 2) which is very low when compared to rats
(see below). These results—especially the reduced
uptake after coinjection of unlabeled exendin—indicate
specific, receptor-mediated tracer binding in the exocrine
pancreas of BALB/c mice. Because of this high exocrine
uptake, [111In]exendin uptake after alloxan treatment was
further investigated in C57Bl/6 mice for validation of the
results described above. Figure 3a summarizes pancreatic
uptake of [111In]exendin in C57Bl/6 mice on various
days after alloxan treatment. After 3 days, a clear
Table 1. Primers used for quantitative PCR on rat and mouse cDNA with the length of amplification on base pairs
Primer Sequence Base pairs
Rat GLP-1R RT
Forward (5′–3′) GGCTCCTCTCGTATCAGGAC 200
Reverse (5′–3′) GATAACGAACAGCAGCGGAAC
Rat GLP-1R std
Forward (5′–3′) ATCCACCTGAACCTGTTTGC 468
Reverse (5′–3′) CTTGGCTATCACGATGCAGA
Mouse GLP-1R RT
Forward (5′–3′) GCGTGGCAGCCAACTACTA 139
Reverse (5′–3′) ATAACGAACAGCAGCGGAAC
Mouse GLP-1R std
Forward (5′–3′) ATCCACCTGAACCTGTTTGC 617
Reverse (5′–3′) AGCTTGATGAAGCGTAGGGT
Rat insulin RT
Forward (5′–3′) TGTGGTTCTCACTTGGTGGA 111
Reverse (5′–3′) CTCCAGTTGTGCCACTTGTG
Rat insulin std
Forward (5′–3′) TGACCAGCTACAGTCGGAA 390
Reverse (5′–3′) GTTGCAGTAGTTCTCCAGTTGG
Mouse insulin RT
Forward (5′–3′) GGAAGCCCCGGGGACCTTCAGA 138
Reverse (5′–3′) GGCGGGTCGAGGTGGGCCTTA
Mouse insulin std
Forward (5′–3′) CACCCAAGTCCCGCCGTGAAG 449
Reverse (5′–3′) TCAGTGGCATTTACACGGTTGCCTA
β-Actin RT
Forward (5′–3′) CTGTACGCCAACACAGTGCT 127
Reverse (5′–3′) GCTCAGGAGGAGCAATGATC
β-Actin std
Forward (5′–3′) AAATCTGGCACCACACCTTC 805
Reverse (5′–3′) CCGATCCACACGGAGTACTT
Rat pdx-1 RT
Forward (5′–3′) GGTATACCAGCGAGATGCT 152
Reverse (5′–3′) TCAGTTGGGAGCCTGATTCT
Rat pdx-1 std
Forward (5′–3′) GAGGACCCGTACAGCCTACA 748
Reverse (5′–3′) GGGACCGCTCAAGTTTGTAA
Mouse pdx-1 RT
Forward (5′–3′) GAGGTGCTTACACAGCGGAA 116
Reverse (5′–3′) GGGCCGGGAGATGTATTTGT
Mouse pdx-1 std
Forward (5′–3′) CCTTTCCCGAATGGAACCGA 679
Reverse (5′–3′) GCTCTCGTGCCCTCAAGAAT
Rat amy2 RT
Forward (5′–3′) ATTGATCTTGGTGGTGAAGCA 174
Reverse (5′–3′) GGCTCTGTCAGTAGGCACAA
Rat amy2 std
Forward (5′–3′) CGAACCAAGGTGGCTGACTAT 636
Reverse (5′–3′) TCGATGTTCACAGACCCAGT
Mouse amy2 RT
Forward (5′–3′) CATGGTGACAAGGTGCAACA 102
Reverse (5′–3′) CAGGTACTGCTTGTTCCTGC
Mouse amy2 std
Forward (5′-3′) TCTGCACAAGGTCTGGAAATGA 500
Reverse (5′–3′) ACCCAGATCAATGACCTCTTGG
Gadph RT
Forward (5′–3′) GCCTGGAGAAACCTGCCAAGTATGA 101
Reverse (5′–3′) AACCTGGTCCTCAGTGTAGCCC
Gadph std
Forward (5′–3′) ATGACTCTACCCACGGCAAG 975
Reverse (5–3′) TGTGAGGGAGATGCTCAGTG
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decrease in pancreatic uptake was observed, while the
maximum decrease was observed 7 days after alloxan
treatment. However, the decrease did not exceed 40 %
compared to control mice injected with vehicle.
Furthermore, similar to the findings observed in BALB/
c mice, tracer uptake in the exocrine pancreas of C57Bl/
6 mice could be blocked with an excess of unlabeled
exendin (Fig. 3b, c). Additionally, the calculated
endocrine-to-exocrine uptake ratio in these mice (4.56 ±
0.91) (Table 2) was in the same range as the ratio
observed in BALB/c mice.
[111In]Exendin Uptake in Different Rat Strains
Figure 4a summarizes the biodistribution (two rats per
strain) of [111In]exendin in four rat strains. In all rat
strains, there was very high lung uptake (910 %ID/g),
which was even higher than the uptake observed in the
kidneys. The biodistribution profiles indicated that WAG/Rij
rats have the highest pancreatic [111In]exendin uptake
(0.45 %ID/g). In addition, the endocrine-to-exocrine uptake
ratio, calculated from the autoradiographs shown in Fig. 4b,
was highest for WAG/Rij rats as well (Table 3). The uptake in
the stomach (1.7 %ID/g) of WAG/Rij rats is relatively high
(Fig. 4a), resulting in a pancreas-to-stomach uptake ratio of
0.27 ± 0.02 (Table 4). Since high stomach uptake might
hamper BCM visualization in vivo, we selected Brown
Norway rats to investigate the beta cell specificity of pancreatic
[111In]exendin accumulation due to their higher pancreas-to-
stomach (1.39 ± 0.11) and acceptable pancreas-to-duodenum
(0.70 ± 0.1) ratios (Table 4) despite their lower pancreatic
uptake (0.27 %ID/g) (Fig. 4a) and endocrine-to-exocrine ratio
(57.1 ± 12.5) (Table 3).
Beta Cell Specificity of [111In]Exendin Uptake in
Brown Norway Rats
In Brown Norway rats, treated with 60 mg/kg alloxan
(two rats), pancreatic uptake was reduced by more than
80 % compared to control rats, that were injected with
vehicle (PBS) (two rats) (Fig. 5). Coadministration of an
excess unlabeled exendin (one rat) reduced the pancre-
atic uptake to similar uptake levels observed in alloxan-
treated rats, suggesting no or very low nonspecific
[111In]exendin uptake in the exocrine pancreas.
Furthermore, autoradiographical analysis showed similar
results: high, specific tracer uptake in the islets of
Langerhans and low, nonspecific uptake in the exocrine
pancreas (Fig. 4b) resulting in an endocrine-to-exocrine
uptake ratio of 57.1 ± 12.5 (Table 4). These results
indicate high beta cell specificity of [111In]exendin in
these rats.
Quantitative PCR
Since receptor-mediated [111In]exendin uptake was ob-
served in exocrine pancreas of mice, Glp-1r mRNA
expression was compared in endocrine and exocrine
pancreatic tissue of rats and mice. Quantitative RT-PCR
revealed similar Glp-1r mRNA expression levels in
Fig. 1 Biodistribution of [111In]exendin in C57Bl/6, BALB/c, NMRI, CBA, and DBA mice. Values are expressed as percentage
injected dose per gram tissue (n = 2). Mice were dissected 4 h after injection.
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endocrine and exocrine tissue of rat and mouse
(Fig. 6a, b) with endocrine-to-exocrine ratios of 45.8
and 55.6, respectively. Individual expression levels of all
cell markers (Glp-1r, Pdx1, Ins, and Amy2b) in endocrine
and exocrine tissue are provided in ESM Fig. 2.
Immunohistochemistry
To investigate GLP-1R expression in endocrine and
exocrine pancreatic tissue, GLP-1R staining was per-
formed on rat, mouse, and human pancreatic tissue.
Figure 6c–e shows the results of the immunohistochem-
ical analysis. In all pancreatic tissues analyzed, the islets
of Langerhans showed clear GLP-1R staining while no,
Table 2. Endocrine-exocrine ratio of [111In]exendin uptake in BALB/c and
C57Bl/6 mice calculated from autoradiography of pancreatic sections
Mouse strain Endocrine-exocrine ratio
BALB/c 4.11 ± 0.93
C57Bl/6 4.56 ± 0.91
Fig. 2 a Biodistribution of [111In]exendin in control and alloxan-treated BALB/c mice. Values are expressed as percentage
injected dose per gram tissue (n = 5 mice). Blocking was performed by coinjection of 25 μg unlabeled exendin (n = 5). b
Pancreatic uptake of [111In]exendin in BALB/c mice treated with 100 mg/kg (n = 5), 150 mg/kg (n = 4), and 200 mg/kg (n = 3) of
alloxan. Values are expressed as percentage injected dose per gram tissue. c Ex vivo autoradiography of pancreatic sections of
BALB/c mice treated with PBS (control) and 50 mg/kg alloxan. Blocking was performed by coinjection of 25 μg unlabeled
exendin.
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or very limited, staining was observed in the exocrine
portion of the pancreatic tissue.
Discussion
In this study, we assessed differences between rodent models
for noninvasive in vivo BCM assessment via GLP-1R
targeting. We investigated the biodistribution of
[111In]exendin in various rat and mouse strains and
determined the specificity of tracer accumulation in the beta
cells. Our present findings indicate that Brown Norway rats
display the most favorable characteristics for noninvasive
BCM assessment using radiolabeled exendin as a tracer.
Mice seem to display receptor-mediated tracer uptake in the
exocrine pancreas, an observation explaining the limited
reduction of exendin uptake in the pancreas of mouse
models after beta cell destruction [22, 24].
In view of the spatial resolution of present imaging
modalities and the small size of the islets, preventing
visualization of single islets in vivo, the optimal model
for in vivo BCM determination must display high and
specific [111In]exendin accumulation in the endocrine
pancreas [29, 30] with no or low uptake in the exocrine
pancreas and surrounding tissues, in particular stomach
and duodenum that are localized in the vicinity of the
pancreas. Since [111In]exendin is excreted via the
kidneys, high tracer uptake is observed in this organ,
which renders accurate quantification of pancreatic tracer
uptake challenging in rodents. However, spillover signal
from the kidneys can be excluded by analyzing a
particular region of interest in the pancreas localized
cranial and anterior of the kidneys [14]. Another option
to overcome spillover effects of the kidneys is
coinjection of a second radiotracer, specifically targeting
the exocrine tissue such as [99mTc]demobesin and L-
[ 1 2 3 I ] i odopheny l a l an ine i n combina t i on wi th
[111In]exendin, which facilitates exact delineation of the
pancreas and therefore improves accurate quantification
of pancreatic [111In]exendin uptake [22]. Of all investi-
gated rat strains, WAG/Rij rats showed the highest
pancreatic [111In]exendin uptake. However, due to their
less favorable pancreas-to-stomach and pancreas-to duo-
denum ratios, WAG/Rij rats are expected to be less
sui ted for in vivo BCM determinat ion using
[111In]exendin SPECT than Brown Norway rats.
To evaluate the beta cell specificity of the tracer, ex vivo
autoradiography was performed. In rats, focal hotspots of
tracer accumulation, representing the beta cells, were
observed while there was a low background signal in the
exocrine tissue (Fig. 4b). Beta cell depletion by alloxan
injection resulted in disappearance of the tracer accumulat-
ing hotspots, confirming beta cell specificity of GLP-1R
targeting using [111In]exendin allowing accurate BCM
determination of BCM. Based on autoradiographic analysis,
we showed endocrine-to-exocrine ratios of 105.7 ± 29.8 in
WAG/Rij rats, 57.1 ± 12.5 in Brown Norway rats, 44.0 ±
13.3 in Sprague Dawley rats, and 44.8 ± 2.9 in F344 rats,
which is in line with previous observations [23].
Furthermore, pancreatic [111In]exendin uptake in Brown
Norway rats is similarly decreased after alloxan-induced
beta cell depletion and coinjection with an excess unla-
beled exendin, confirming beta-cell-specific tracer accu-
mulation in this model. We have previously shown clear
differences in [111In]exendin uptake in the pancreas of
Brown Norway rats treated with various concentrations of
alloxan, resulting in a linear correlation of SPECT signal
and BCM [14]. These observations confirm that this rat
strain provides an optimal model for in vivo BCM
assessment via GLP-1R targeting.
Several groups have reported a decrease in pancreatic
tracer uptake in mice after alloxan or streptozotocin-
induced beta cell destruction [22, 24]. However, the
maximum decrease did not exceed 40 %, an observation
which can be explained by our data. After coinjection of
an excess unlabeled exendin in mice, tracer uptake was
much lower than the remaining uptake observed after
alloxan-induced beta cell depletion. These results strongly
suggest that the limited decrease in tracer uptake after
alloxan-induced beta cell destruction is caused by
receptor-mediated [111In]exendin uptake in the exocrine
Fig. 3 a Pancreatic uptake of [111In]exendin in C57Bl/6 mice
(n=2) on different days after alloxan treatment (50 mg/kg). b
Pancreatic uptake of [111In]exendin in C57Bl/6 mice treated
with vehicle (control) (n=2) and 50 mg/kg alloxan (n=2).
Blocking was performed by coinjection of 25 μg unlabeled
exendin (n=1). c Autoradiography of pancreatic sections of
C57Bl/6 mice treated with vehicle (control) and 50 mg/kg
alloxan. Blocking was performed by coinjection of 25 μg
unlabeled exendin.
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pancreas of mice. Nevertheless, there was no detectable
GLP-1R expression in exocrine pancreatic tissue of mice
by immunohistochemistry and only very low Glp-1r
mRNA express ion was obse rved by RT-PCR.
Furthermore, endocrine-to-exocrine ratios of Glp-1r
mRNA expression are similar in mice and rats. These
Fig. 4 a Biodistribution of [111In]exendin in Sprague Dawley, F344, Wag/Rij, and Brown Norway rats. Values are expressed as
percentage injected dose per gram tissue (n = 2 rats). Rats were dissected 4 h after injection. b Autoradiography of pancreatic
section of Sprague Dawley, F344, Wag/Rij, and Brown Norway rats showing focal hotspots of tracer accumulation representing
the islets.
Table 3. Overview of the endocrine-exocrine ratios of [111In]exendin
uptake in various rat strains calculated from autoradiography of pancreatic
sections
Rat strain Endocrine-exocrine ratio
WAG/Rij 105.66 ± 29.84
Brown Norway 57.06 ± 12.53
Sprague Dawley 44.00 ± 13.33
F344 44.83 ± 2.85
Table 4. Overview of the pancreas-to-stomach and pancreas-to-duodenum
ratios of [111In]exendin uptake in the different rat strains
Rat strain Pancreas-to-stomach
ratio
Pancreas-to-duodenum
ratio
Sprague Dawley 0.08 ± 0.02 0.33 ± 0.02
F344 0.11 ± 0.00 0.31 ± 0.07
Wag/Rij 0.27 ± 0.02 1.15 ± 0.78
Brown Norway 1.39 ± 0.11 0.70 ± 0.10
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observations suggest that [111In]exendin probably binds
to a receptor other than the GLP-1R in the exocrine
pancreatic tissue of mice, which could also explain the
observations of Nalin et al. [31]. These findings preclude
the use of this model for additional characterization of
[111In]exendin uptake. In contrast with observations in
mice after beta cell destruction [22, 24] (present data),
and similar to the above described rat data, patients with
long standing type 1 diabetes can show very low
[111In]exendin uptake similar to background values [14],
suggesting no or negligible uptake in the exocrine
pancreas. Therefore, the situation in humans appears to
be better reflected by rat models than by mouse models.
At this point in time, it remains unclear which receptor
is responsible for exendin uptake in the exocrine
pancreas of mice but it is highly likely that this receptor
shows differences with the rat and human receptors in a
way that only the variant expressed in mice can bind
exendin.
Conclusion
The choice of a certain rodent model can greatly influence
studies investigating BCM dynamics. The present findings
indicate that mice have binding in the exocrine pancreas
which is mediated by a receptor that is not the GLP-1R,
rendering them an inadequate model for BCM assessment by
radiolabeled exendin. On the other hand, rats do not show
receptor-mediated exendin binding in the exocrine pancreas,
and are therefore a better suited model for further studies.
Among the investigated rat models, Brown Norway rats are
the optimal model for noninvasive GLP-1R targeting given
their favorable pancreas-to-background uptake ratios. In
view of these results and the very low remaining uptake in
patients with T1D, rats appear to display better characteris-
tics for in vivo investigation of BCM dynamics when
compared to mice, and are thus considered a suitable model
better reflecting the human situation than other animal
models.
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Fig. 5 Pancreatic uptake of [111In]exendin in Brown Norway
rats treated with vehicle (control) (n = 2) and alloxan (60 mg/
kg) (n = 2). Values are expressed as percentage injected dose
per gram tissue. Blocking was performed by coinjection of
25 μg unlabeled exendin (n = 1).
Fig. 6 Quantitative PCR for the Glp-1r in endocrine and
exocrine pancreatic tissue of a rat and b mouse and
immunohistochemical analysis of GLP-1R expression in
pancreatic tissue (embedded in paraffin) of c rat, d mouse,
and e human. Both analyses show high GLP-1R expression
in the islets and no, or very low expression in exocrine tissue.
For quantitative PCR, paired t test was performed and
p G 0.05 was considered as significant.
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